The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 11: 1526 - 1530

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.11.010

Basic Research

Dapagliflozin inhibits angiotensin Ⅱ⁃induced cardiomyocyte hypertrophy and apoptosis

  • Shuangyin SHAO ,
  • Xintong CAI ,
  • Lili XIAO ,
  • Lu. GAO
Expand
  • *.Department of Cardiac Surgery，He′nan Thoracic Hospital，Zhengzhou 450008，China

Received date: 2023-08-02

  Online published: 2024-06-13

Fold

Abstract

Objective This study aimed to investigate the effect of Dapagliflozin on the hypertrophy and apoptosis of cardiomyocytes induced by angiotensinⅡ（Ang Ⅱ）. Methods Primary rat neonatal cardiomyocytes were isolated， cultured and randomly divided into 4 groups： control group， Ang Ⅱ group， dapagliflozin group 1 （0.5 μmol/L）， and dapagliflozin group 2 （2 μmol/L）. α-actin staining was used to detect cell area. qPCR was applied to detect embryonic gene transcription. Tunel staining was adopted to detect cell apoptosis level. The caspase3 kit was used to detect caspase3 activityand western blotting was used to detect classical signal molecules. Results The cell surface area of the Ang Ⅱ group was significantly larger than that of the control group （P < 0.05）. The cell surface area of the dapagliflozin group 1 and the dapagliflozin group 2 was significantly lower than that of the Ang Ⅱ group （P < 0.05）. The results of qPCR showed that the fetal gene transcription of Ang Ⅱ group was significantly higher than that of the control group （P < 0.05）； the fetal gene transcription of dapagliflozin group 1 and dapagliflozin group 2 was lower than that of Ang Ⅱ group （P < 0.05）. Tunel staining showed that the number of apoptosis in the Ang Ⅱ group was higher than that in the control group （P < 0.05）； the number of apoptosis in the dapagliflozin group 1 and the Dapagliflozin group 2 was lower than that in the Ang Ⅱ group （P < 0.05）. The caspase3 activity of the cells in the Ang Ⅱ group was higher than that of the control group （P < 0.05）but lower in dapagliflozin group 1 and the dapagliflozin group 2 （P < 0.05）. The results of Western blotting showed that the activation of insulin-like growth factor 1 receptor （IGF1R） and Akt in the Ang Ⅱ group was lower than that in the control group （P < 0.05）but increased in the dapagliflozin group 1 and 2 cells （P < 0.05）. Conclusion Dapagliflozin could directly act on cardiomyocytes to protect them from Ang Ⅱ-induced damage.

Key words： dapagliflozin; SGLT2 inhibitor; angiotensin Ⅱ; cardiomyocytes; insulin-like growth factor 1 receptor

Cite this article

Shuangyin SHAO , Xintong CAI , Lili XIAO , Lu. GAO . Dapagliflozin inhibits angiotensin Ⅱ⁃induced cardiomyocyte hypertrophy and apoptosis[J]. The Journal of Practical Medicine, 2024 , 40(11) : 1526 -1530 . DOI: 10.3969/j.issn.1006-5725.2024.11.010

References

1 RICHALET J P， HERMAND E， LHUISSIER F J. Cardiovascular physiology and pathophysiology at high altitude［J］. Nat Rev Cardiol， 2023， 21（2）：75-88. doi:10.1038/s41569-023-00924-9
2 郑文善， 汪材山， 赵凯， 等. 指南导向药物“新四联”治疗慢性心力衰竭的临床体会［J］. 实用医学研究， 2023， 5（1）：45-47. doi:10.12346/pmr.v5i1.8146
3 LAM C S P， DOCHERTY K F， HO J E， et al. Recent successes in heart failure treatment［J］. Nat Med， 2023， 29（10）：2424-2437. doi:10.1038/s41591-023-02567-2
4 MORALES J， HANDELSMAN Y. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease： JACC Review Topic of the Week［J］. J Am Coll Cardiol， 2023， 82（2）：161-170. doi:10.1016/j.jacc.2023.04.052
5 PARK J J， GREENBERG B. Topping Off the Pill Box： Dapagliflozin， Heart Failure， and Polypharmacy［J］. JACC Heart Fail， 2023， 11（10）：1394-1396. doi:10.1016/j.jchf.2023.06.033
6 AROW M， WALDMAN M， YADIN D， et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy［J］. Cardiovasc Diabetol， 2020， 19（1）：7. doi:10.1186/s12933-019-0980-4
7 CHEN K， NIE Z， SHI R， et al. Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure［J］. JAMA Netw Open， 2023， 6（8）：e2330754. doi:10.1001/jamanetworkopen.2023.30754
8 MUKHERJEE D. In HF， with or without PAD， dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputations［J］. Ann Intern Med， 2023， 176（9）：JC99. doi:10.7326/j23-0066
9 KONDO T， WANG X， YANG M， et al. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure［J］. J Am Coll Cardiol， 2023， 82（10）：1014-1026. doi:10.1016/j.jacc.2023.05.056
10 WEINTRAUB W S. Improving the Quality of Life for Patients With Heart Failure and Preserved Ejection Fraction［J］. J Am Coll Cardiol， 2023， 81（5）：474-476. doi:10.1016/j.jacc.2022.11.032
11 BIEGUS J， FUDIM M， SALAH H M， et al. Sodium-glucose cotransporter-2 inhibitors in heart failure： Potential decongestive mechanisms and current clinical studies［J］. Eur J Heart Fail， 2023， 25（9）：1526-1536. doi:10.1002/ejhf.2967
12 SHI L， ZHU D， WANG S， et al. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload［J］. Am J Hypertens， 2019， 32（5）：452-459. doi:10.1093/ajh/hpz016
13 O'HARA D Vand JARDINE M J. SGLT2 inhibitors may prevent diabetes［J］. Nat Rev Nephrol， 2022， 18（4）：203-204. doi:10.1038/s41581-022-00541-8
14 MOURA F A， BERG D D， BELLAVIA A， et al. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes［J］. Diabetes Care， 2023， 46（10）：1807-1815. doi:10.2337/dc23-0492
15 徐敏， 李兴旺， 卢海龙， 等. 达格列净或阿卡波糖联合二甲双胍对老年T2DM患者糖代谢和心功能的临床观察［J］. 医学研究杂志， 2021， 50（3）：110-113，132.
16 JHUND P S， KONDO T， BUTT J H， et al. Dapagliflozin across the range of ejection fraction in patients with heart failure： a patient-level， pooled meta-analysis of DAPA-HF and DELIVER［J］. Nat Med， 2022， 28（9）：1956-1964. doi:10.1038/s41591-022-01971-4
17 DOCHERTY K F， OGUNNIYI M O， ANAND I S， et al. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction［J］. JACC Heart Fail， 2022， 10（1）：52-64. doi:10.1016/j.jchf.2021.08.006
18 FERNANDEZ-RUIZ I. Dapagliflozin improves outcomes in HFmrEF and HFpEF［J］. Nat Rev Cardiol， 2022， 19（11）：719. doi:10.1038/s41569-022-00782-x
19 PASCUAL-FIGAL D A， ZAMORANO J L， DOMINGO M， et al. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure： The DAPA-MODA study［J］. Eur J Heart Fail， 2023， 25（8）：1352-1360. doi:10.1002/ejhf.2884
20 NIKOLAOU P E， MYLONAS N， MAKRIDAKIS M， et al. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury： a class or a drug effect？［J］. Basic Res Cardiol， 2022， 117（1）：27. doi:10.1007/s00395-022-00934-7
Options
Outlines

/

〈 〉